The current medical reality of cancer gene therapy is reflected by more than ten approved
products on the global market, including oncolytic and other viral vectors and CAR T-cells as …

Background: Glioblastoma multiforme (GBM) is a WHO grade 4 glioma and the most
common malignant primary brain tumour. Recently, there has been outstanding progress in …

Mesenchymal stem cells (MSCs), as self-renewing multipotent stromal cells, have been
considered promising agents for cancer treatment. A large number of studies have …

Purpose: Mesenchymal stem cells (MSC) have emerged as cellular-based vehicles for the
delivery of therapeutic genes in cancer therapy based on their inherent tumor-homing …

Cloning of the sodium iodide symporter (NIS) in 1996 has provided an opportunity to use
NIS as a powerful theranostic transgene. Novel gene therapy strategies rely on image …

New treatment strategies are urgently needed for glioblastoma (GBM)—a tumor resistant to
standard-of-care treatment with a high risk of recurrence and extremely poor prognosis …

Sodium iodide symporter (NIS) gene transfer for active accumulation of iodide in tumor cells
is a powerful theranostic strategy facilitating both diagnostic and therapeutic application of …

Simple Summary Glioblastoma (GBM) is the most common glioma, which belongs to the
aggressive and malignant type of brain tumor. Conventional treatments such as surgical …

Improved therapeutic strategies are required to minimize side effects associated with
radioiodine gene therapy to avoid unnecessary damage to normal cells and radiation …

Radioactive iodine therapy (RIT) is an effective, safe, and cheap method in benign and
malignant thyroid diseases. There is still an unresolved question of whether RIT treatment …